Intraocular tumours continue to pose diagnostic problems which are not mitigated by the rarity of such cases in the experience of the ophthalmologist. Clinical examination and observation of the natural history of intraocular lesions do not always offer a definitive diagnosis, and laboratory and other tests are needed to provide further information. The successful application of radio-isotopes in the investigation of malignancy elsewhere in the body has invited their introduction into the realm of ophthalmology.
drin and his initial reports of its use for indicating the presence of intraocular tumours were encouraging.
Methods and apparatus
The present series of cases is divided into two groups according to the apparatus employed for the detection of the y-emission. The scintillation probe in both groups comprised a thallium-activated sodium iodide crystal and photomultiplier within a steel sheath. To the front of the probe was attached an open lead cylinder I cm. in diameter and in length. In group I, the probe was connected to an Ekco ratemeter and in Group 2 to the more accurate Harwell 2000 series scaler. The night before the test, an intramuscular injection of I ml. Mersalyl was given to the patients to block renal uptake of the isotope. On the day of the test 500 ,ug. I97 Hg Chlormerodrin was injected intravenously and readings were taken over a period of 8 hours, and again at 24 hours after the injection.
Gi-Op I
The average count rates were recorded over a period of 2 minutes on the Ekco ratemeter (time constant 30 sec.). The probe was successively placed in front of each eye and also against a fixed position on the forehead which acted as a reference point for background activity.
Gioup 2 Readings were taken over 3 to 6 periods each of 30 sec. The total count over each side was recorded on the Harwell scaler and the average total count per minute for each eye was calculated.
Y. M. Cappin and D. P. Greaves
Our final results (Tables I to V) (Table II) , six with benign non-inflammatory lesions (Table IV) , four with benign lesions in congested eyes (Table V) , and three with normal eyes (Table   III) . Six clinically diagnosed malignant melanomas were examined before radiotherapy (Table II) and five (83.5 per cent.) showed significantly increased uptakes at 3 hrs and afterwards. The other (Case 6) showed no significant difference because of widely +9-6 (-ooi) To compare with the above cases of 'active' melanoma, the last (Case 7) was examined some 2 years after radiotherapy for a malignant melanoma which appeared to be clinically quiescent, and is still unchanged 5 years later. No increased uptake in the affected eye was recorded. The control series (Table III) comprised three cases with completely normal eyes undergoing Chlormerodrin brain scans in whom further investigation failed to reveal the presence of intracranial tumours. No significant difference between the two eyes was demonstrated at any interval. Furthermore, no significant increase in uptake was found in the affected eyes of six patients with benign non-inflammatory pathology (Table IV) . However, in four cases with benign pathology associated with gross congestion or inflammation, the affected eye registered pronounced increased uptakes as in the first series (Table V) .
Discussion
Mercury I97 Chlormerodrin, which has been widely employed in brain and kidney scanning, offers many advantages (Sodee, I963; Rhoton, Carlsson, I964; Takahashi, Nofal, and Beierwaltes, I966; Bollini and Tori, I964) . It has a short half-life of 64 hrs and the kidney and other essential organs absorb only a low dose of radiation, e.g. the kidney receives only 3.5 r per mc. Chlormerodrin. Its rapid clearance from the body, (body half-life about I5 hrs) reduces the background levels from the cavernous sinuses especially for the later readings of the test. With this compound Sodee (i963, I964) reported a go per cent. relatively increased uptake of isotope in eyes containing tumours, but Leopold, Keates, and Charkes (I964) found a level of only 40 per cent. in one case out of nine. In only two of our cases did we obtain the levels of uptake similar to Sodee's, but different techniques of measurement were employed.
Our early experience with the ratemeter demonstrated a consistently increased uptake, albeit of variable degree, in seven out of eight tumour-bearing eyes, (Greaves and Cappin, I 968) . With the Harwell scaler an important advantage was obtained. This instrument summates the emitted particles (whose energy is selected by a pulse height analyser) by contrast to the ratemeter, which averages the emission over a chosen period. The count levels obtained in our second series were considerably higher and susceptible to statistical analysis.
Our continuing experience with this technique has amplified our previous report. In the present series nineteen out of 24 cases of proven intraocular tumour gave a definite positive result with a significantly increased uptake at 5 hours and afterwards, and a further three offered suggestive results, together making 92 per cent. Only in two cases were there false negatives. These may have been due to the small size of the tumour or to poor co-operation of the patient during the test with scattering of individual readings at each interval. Some movement of the head of the pat ent relative to the probe was almost certainly the cause of scattering in the three cases with suggestive results.
Significant results were obtained in five out of six cases of clinically diagnosed but not histologically verified melanoma. The results in the one false negative case were again marred by lack of patient co-operation. No significant difference in uptake between the eyes of normal patients and those of patients with quiet benign intraocular lesions could be demonstrated, and in the latter an affected eye might even show significantly lower uptakes than the normal eye. However, all inflamed eyes showed markedly elevated counts, thus producing false positive results, as other investigators have found when using radioisotope techniques. Leopold and others (I964) and Sodee (I963) utilized a focusing collimator, dividing the eye into octants and counting each segment individually. Leopold's measurements gave counts of the order of I00 and he did not achieve any success with this method. We also initially tried a narrow-beam focusing collimator, but as this did not give useful results we began recording whole eye counts with a large collimator; these counts were of the order of 5,000 to 8,ooo per half minute at 7 hrs and 1,500 to 2,000 at 24 hrs.
It was not possible to correlate the levels of uptake with the type of tumour, its position, degree of necrosis, or vascularity. As already noted, there was a tendency for smaller tumours to show a lesser percentage of difference of uptake.
The incidence of positive results in brain scans employing 197Hg Chlormerodrin is of a similar order to that in our own series, being about 85 per cent. for metastatic tumours, and possibly even higher for glioblastomas (Rhoton, Eichling, I966) . Widely varying reports of 32p studies and their efficiency have been published. With a counter-probe in front of the globe, very poor results have been obtained with 32p, probably owing to the poor penetration of tissues by I rays, and Leopold and others (I964) have summarized the results of several papers concerning these techniques. With a counterprobe placed behind the globe, some 89 per cent. of intraocular tumour-bearing eyes yielded positive results. Newell, Goren, Brizel, and Harper (i 963) examined the ocular uptake of 1251 diiodofluorescein in a series of cases and obtained fifteen positive results from nineteen patients (79 per cent.; these workers reported no false positive results in a further series of twenty cases with non-inflammatory benign ocular conditions. In our earlier series of seven patients (Greaves and Cappin, I968), we were unable to obtain similar results with this technique.
Though many papers have recently been published demonstrating supposedly characteristic fluorescein angiographic features of choroidal malignant melanomas, few give any indication of the accuracy of the method in helping to substantiate the clinical diagnosis. Furthermore, the angiographic criteria for distinguishing between malignant melanomas and haemangiomas are not rigid. Pettit, Barton, Foos, and Christensen (I 970) found a characteristic fluorescence pattern in 31 out of 36 cases of malignant melanomas (86 per cent.). Our results with Chlormerodrin compare favourably with this and the results obtained with other isotopes.
In addition to the facility with which the test can be performed, Tenon's capsule need not be opened to enable a probe to be passed behind the globe, nor is there need for such accurate positioning of the probe as is required for the 32p test. There is the added advantage that our test can also be used for eyes with opaque media when fluorescein angiography is obviously precluded and 32p testing is difficult to perform with accuracy.
There are few laboratory techniques which can offer absolute confirmation of a clinically established diagnosis, and even these are only valuable under rigidly defined conditions. Our technique will distinguish between benign and malignant intraocular tumours in the majority of cases provided that inflammation is not present to mask the results.
Future developments in this field will necessitate a deeper understanding of tumour metabolism and the choice of compounds or specific metabolites appropriately labelled. We are currently engaged in investigating the diagnostic potentialities of other isotopically labelled compounds.
Eye scanning was performed on two groups of patients who had received intravenous 197Hg Chlormerodrin.
In the first series, five out of six patients with histologically proven malignant melanoma, two cases of ocular metastasis, and one case of clinically diagnosed malignant melanoma, all showed a marked increase in uptake in the affected eye compared with the normal. Two patients with inflammatory benign lesions also showed an increased uptake in the affected eye. In the second series, 79 -2 per cent. of histologically proven intraocular tumours and 83 5 per cent. of clinically diagnosed malignant melanomas gave definitely positive tests. One case of previously treated clinically quiescent malignant melanoma, three subjects with normal eyes, and six patients with benign non-inflammatory lesions yielded negative tests. Four patients with benign inflammatory lesions produced false positive results.
